fbpx
Monday, November 30th, 2020
Home » Shipping » COVAXX and Maersk enter partnership to supply COVID-19 vaccines globally

COVAXX and Maersk enter partnership to supply COVID-19 vaccines globally

PortandTerminal.com, October 27, 2020

“Efficient and safe delivery of COVID-19 vaccines around the world is the most urgent logistics challenge we face today” – COVAXX

HAUPPAUGE, NY — COVAXX, a U.S. company developing a vaccine to fight COVID-19, has announced a global logistics partnership with Maersk, one of the world’s largest shipping and integrated logistics providers. The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities. Financial terms of the agreement are not disclosed.

COVAXX is developing UB-612 using a high precision, synthetic peptide platform to activate both B-cell and T-cell arms. The investigational vaccine is designed to mimic natural biology and preclinical studies have shown high immunogenicity and levels of neutralizing titers against SARS-CoV-2. The technology platform has been successful in commercializing blood diagnostics as well as safe and effective vaccines for infectious disease in animal health and has been tested in numerous clinical trials for other indications to date.

The company has advanced pre-commitments for over 100 million doses of UB-612 around the globe

COVAXX is currently conducting Phase 1 clinical trials of UB-612 in Taiwan and has an agreement with the University of Nebraska Medical Center to conduct Phase 2 trials in the United States, upon regulatory approval. The company has advanced pre-commitments for over 100 million doses of UB-612 around the globe. In September, COVAXX announced an agreement with Dasa, the largest diagnostic medical company in Brazil to conduct a large-scale human efficacy clinical trial in Brazil.

Agreement provides for end-to-end supply chain management

The mission of COVAXX is to defeat COVID-19 and ultimately democratize health worldwide. Maersk will help fulfill this mission by overseeing all logistics activities to ensure efficient transportation to developing countries. The agreement provides for end-to-end supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain. COVAXX is planning to manufacture 100 million doses of UB-612 during early 2021, and a billion doses by the end of 2021. The design of the vaccine components will allow for the use of existing cold-chain storage and distribution channels, as the COVAXX vaccine does not require additional infrastructure such as -80⁰C freezers or liquid nitrogen tanks to store materials at extreme temperatures.

Other articles you may find interesting

Copyright © 2020 PortandTerminal.com

Check Also

Section of car carrier being lifted onto a barge

The first slice of the Golden Ray wreck cut and lifted onto barge (PHOTOS)

PortandTerminal.com, November 29, 2020 BRUNSWICK, GA – Crews have finished cutting and lifting the first …

Red Helicopter

Man flown to hospital after 100 ft fall from ladder on cargo ship – Port of Houston

PortandTerminal.com, November 30, 2020 HOUSTON — Local media are reporting that a man was taken …